(XDJP) Xtrackers Nikkei 225 1D - Ratings and Ratios
Equities, Replication, Nikkei, Tokyo
Dividends
| Dividend Yield | 1.36% |
| Yield on Cost 5y | 1.91% |
| Yield CAGR 5y | 7.59% |
| Payout Consistency | 85.5% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 16.9% |
| Value at Risk 5%th | 27.1% |
| Relative Tail Risk | -2.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 7.16 |
| CAGR/Max DD | 0.78 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.380 |
| Beta | 0.210 |
| Beta Downside | 0.363 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.18% |
| Mean DD | 4.65% |
| Median DD | 4.23% |
Description: XDJP Xtrackers Nikkei 225 1D December 01, 2025
The Xtrackers Nikkei 225 UCITS ETF (1D) (XETRA: XDJP) seeks to track the Morningstar Japan TME NR JPY index, which mirrors the performance of the 225 most liquid large-cap Japanese equities listed on the Tokyo Stock Exchange First Section.
Index constituents are reviewed regularly for liquidity and sector balance. Liquidity is measured by ranking each stock’s trading volume and price-movement magnitude over the prior five years, ensuring the ETF holds highly tradable shares and can adapt to structural shifts in Japan’s economy.
Replication is achieved by purchasing the index constituents in the same weightings determined by Deutsche Asset Management (UK) Limited, with the option to hold a “substantial number” of the stocks if full replication proves impractical.
Key market drivers to watch: • The Nikkei 225 has risen ~12 % year-to-date (2025) as the yen weakens against the dollar, boosting export-oriented earnings. • Technology (electronics, robotics) and consumer discretionary remain the two largest sector exposures, together accounting for roughly 45 % of the index weight. • Bank of Japan’s shift away from negative rates toward a modest policy rate hike could tighten financing conditions for corporates, influencing valuation multiples.
For a deeper, data-driven breakdown of the ETF’s risk-adjusted performance and sector sensitivities, you may find the analytics on ValueRay worth a quick look.
What is the price of XDJP shares?
Over the past week, the price has changed by +2.10%, over one month by +0.53%, over three months by +5.42% and over the past year by +14.29%.
Is XDJP a buy, sell or hold?
What are the forecasts/targets for the XDJP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 31.7 | 11.6% |
XDJP Fundamental Data Overview December 21, 2025
Market Cap EUR = 269.70b (269.70b EUR * 1.0 EUR.EUR)
Beta = 0.0
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 269.70b EUR (269.70b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 269.70b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 269.70b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.79% (E(269.70b)/V(269.70b) * Re(6.79%) + (debt-free company))
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)